Obesity Treatments
60 articles on Obesity Treatments, researched and written by the Shotlee Editorial Team from primary sources.
Novo Nordisk Sues Eli Lilly Over Which GLP-1 Sheds the Most Pounds
Novo Nordisk has filed a federal lawsuit against Eli Lilly, alleging deceptive advertising regarding the comparative weight loss efficacy of Zepbound and Wegovy. The dispute centers on dosage comparisons and clinical trial data interpretation.
8 min read
AI Helps Stanford Scientists Discover Natural Ozempic Without the Usual Side Effects
Stanford Medicine researchers have identified a naturally occurring molecule that may suppress appetite and reduce body weight in a way that resembles semaglutide, the active ingredient in Ozempic.
8 min read
Ozempic Maker Novo Nordisk Sues Eli Lilly Over 'Materially Misleading' Ads
Novo Nordisk has filed a lawsuit against Eli Lilly, alleging deceptive advertising regarding weight-loss drugs. This legal battle highlights the intense competition between semaglutide and tirzepatide.
9 min read
Semaglutide Supply Chain Halted: What Dr. Reddy's API Issue Means for You
Dr. Reddy's Laboratories has paused semaglutide shipments due to active ingredient quality concerns. Here is a deep dive into the impact on the GLP-1 market and patient care.
7 min read
Ozempic, Wegovy, Mounjaro: Navigating the New GLP-1 Landscape
The landscape of GLP-1 medications for weight loss and chronic disease management is rapidly evolving. From new access programs to shifting pricing dynamics, understanding these advancements is crucial for patients and healthcare providers alike.
6 min read
Ozempic, Wegovy, Mounjaro: Why Rhode Island Medicaid Must Cover Obesity Meds
Rhode Island's strategic health initiatives are commendable, but a recent budget proposal to cut Medicaid coverage for GLP-1 obesity treatments like Ozempic and Wegovy raises serious concerns. This decision, while seemingly a cost-saving measure, risks long-term health consequences and increased healthcare expenditures.
6 min read
Beyond BMI: Why Mounjaro Eligibility is More Complex Than You Think
Many assume BMI is the sole determinant for Mounjaro prescriptions, but the reality is far more nuanced. This article explores the comprehensive health criteria healthcare providers use to ensure safe and effective treatment.
6 min read
AI Startup Acquires Parkinson's Cell Therapy from Ozempic Maker
Mark Zuckerberg-backed AI startup Cellular Intelligence has acquired global rights to STEM-PD, an experimental Parkinson's disease cell therapy developed by Novo Nordisk, the pharmaceutical giant behind Ozempic and Wegovy. This strategic move signals a new era for AI in accelerating complex therapeutic development.
7 min read
GLP-1 Drugs vs. Weight Loss Surgery: A Shifting Landscape
New research indicates a significant decline in bariatric surgeries, coinciding with the rise of GLP-1 medications. This article delves into the implications, comparing the efficacy and cost-effectiveness of these treatments and offering guidance for patients.
7 min read
Medicaid GLP-1 Coverage Changes: Access to Ozempic and Wegovy
A growing number of state Medicaid programs are restricting or eliminating coverage for GLP-1 medications like Ozempic and Wegovy for obesity treatment due to budget constraints.
8 min read
Survodutide Shines: Dual GLP-1/Glucagon Agonist Shows Major Weight Loss
Zealand Pharma and Boehringer Ingelheim announced breakthrough Phase 3 results for survodutide, a dual GLP-1 and glucagon receptor agonist, demonstrating significant weight reduction and metabolic improvements in adults with obesity or overweight.
7 min read
New AI-Discovered Molecule Offers Potential Ozempic/Wegovy Alternative
A groundbreaking discovery using artificial intelligence has identified a naturally occurring molecule, BRP, that targets the brain's appetite center, potentially offering a new and improved alternative for weight management compared to current GLP-1 medications.
7 min read
Pfizer's Xianweiying GLP-1 Weight Loss Drug Pre-Order in China
Pfizer's GLP-1 weight management drug Xianweiying is available for pre-order on JD.com in China, intensifying rivalry in a market projected to reach billions. Priced at 489 yuan ($72) for a 1.2 ml injector pen with shipping from April 27, it challenges leaders like Novo Nordisk's Wegovy and Innovent's Xinermei. This move bolsters Pfizer's position via licensing from Sciwind.
5 min read
Beyond GLP-1Rs: Emerging Targets to Surge 50-Fold in Obesity Market
While GLP-1R agonists like semaglutide (Wegovy) and tirzepatide (Zepbound) dominate the obesity market, non-GLP-1R targets are poised for explosive growth. Sales for these alternatives are expected to surge almost 50-fold from $310m in 2026 to $15.5bn in 2031, driven by calcitonin receptor drugs. This diversification signals a reshaping of the $172.6bn obesity pharmaceutical landscape by 2031.
5 min read
China's Pharma Dominance Is Just Beginning
The pharmaceutical world is shifting: China has surged past the US in early-stage drug research, with programs jumping over 600% since 2015. This rapid growth promises cheaper, innovative treatments like advanced obesity drugs potentially better than Ozempic—but raises questions on access and geopolitics for patients worldwide.
5 min read
Eli Lilly Eyes India Rollout for Oral Obesity Drug Orforglipron
US drugmaker Eli Lilly is set to bring orforglipron, a game-changing oral weight-loss pill, to India following successful global trials that included Indian patients. With obesity rates surging, this daily GLP-1 therapy promises easier access than injectables like Mounjaro. Explore the trial data, market insights, and what it means for patients.
5 min read
Eli Lilly Launches Oral GLP-1 Foundayo Across US via LillyDirect
Eli Lilly has launched Foundayo, its innovative oral GLP-1 drug, directly to U.S. consumers via LillyDirect and major telehealth providers. This once-daily pill offers convenient obesity treatment alongside diet and exercise, with average weight loss of 27 pounds at the highest dose. Now available through Amazon Pharmacy's same-day delivery and more, it's set to challenge Novo's Wegovy dominance.
5 min read
Emcure Revises Poviztra Semaglutide Price to ₹3,999/Month in India
Emcure Pharmaceuticals is slashing the price of Poviztra semaglutide injection to ₹3,999 per month starting April 3, 2026, making this weight management therapy more accessible across India. As the first Indian firm offering this second brand of Novo Nordisk's semaglutide, Emcure aims to tackle the nation's obesity epidemic affecting over 600 million adults. Backed by 49 million patient years and 50 clinical trials, Poviztra promises validated support for obesity-linked conditions.
5 min read
Entrepreneur Uses AI to Build $1B Telehealth Company on GLP-1 Drugs
Matthew Gallagher, a 41-year-old LA entrepreneur, turned $20,000 into a nearly $2 billion telehealth empire with AI alone. Medvi sells GLP-1 drugs like Ozempic at $300 versus $1,000 retail, serving 250,000 customers. But rapid growth sparks debates on legality and fake ads.
5 min read
Wegovy Data Challenges Foundayo, Resets Novo Valuation Debate
Novo Nordisk released new cross-trial data showing its oral Wegovy pill delivers greater weight loss than Eli Lilly's newly FDA-approved Foundayo obesity pill. With fewer adverse events and strong patient preference for Wegovy, this first direct comparison challenges Foundayo's profile. The findings arrive amid volatile CPSE:NOVO B stock performance, resetting valuation debates.
5 min read
Wegovy's New Subscription Saves Up to $1,200/Year – Not for Everyone
Novo Nordisk has launched a new subscription program for Wegovy, promising up to $1,200 in yearly savings on injections to help patients maintain access to this GLP-1 obesity drug. With plans starting at $249 per month for 12 months, it targets self-pay users facing cost uncertainty. But eligibility limits mean it's not for everyone—here's what you need to know.
4 min read
West Pharmaceuticals Expands Dublin Site, Creates 330 Jobs for GLP-1
West Pharmaceuticals is expanding its Dublin manufacturing site, adding 330 high-skilled jobs to meet surging demand for drug delivery solutions in diabetes and obesity treatments. The 165,000 square foot facility upgrade focuses on containment and delivery systems for injectables, including next-generation GLP-1 therapies like those used in semaglutide drugs. This move strengthens Ireland's role in global metabolic health supply chains.
5 min read
Kailera Therapeutics Eyes IPO for Obesity Drug Pipeline
Boston-based Kailera Therapeutics is gearing up for an IPO to fuel its obesity drug pipeline, including Phase III GLP-1/GIP agonist ribupatide. Backed by $400M Series A and $600M Series B, the company eyes superior profiles versus blockbusters like Zepbound. Despite $368.7M deficits, topline data looms large.
5 min read
Mars CEO Poul Weihrauch Named Novo Nordisk Board Observer
In a strategic move, Novo Nordisk has elected Poul Weihrauch, CEO of Mars, as a board observer to enhance its consumer presence in the competitive US obesity market. This comes alongside new board members and a 2025 leadership overhaul. The appointment underscores efforts to make Wegovy more accessible through telehealth and direct-to-consumer channels.
5 min read
Ozempic Goes Generic Worldwide, But Not in U.S. Until 2030
Ozempic, the blockbuster semaglutide drug from Novo Nordisk, is set to go generic in India as early as this weekend, with China, Brazil, Turkey, and South Africa following. This could drop prices to $15 per month, opening access to millions with obesity and diabetes. Meanwhile, U.S. and Europe face delays until 2030 due to patent extensions.
5 min read
Boston Mayor Wu, Unions Limit GLP-1 Coverage for Weight Loss Drugs
Boston Mayor Michelle Wu announced a deal with unions to implement prior authorization for GLP-1 weight loss drugs like Ozempic and Wegovy, saving the city $10.6 million. This move addresses skyrocketing health costs that threatened 22.6% premium hikes. City workers must now get approval for coverage on these popular obesity treatments.
5 min read
Eli Lilly's Employer Connect: Unlocking GLP-1 Demand
Eli Lilly is dominating the GLP-1 market with 25% projected growth in 2026, outpacing Novo Nordisk's decline. Their new Employer Connect platform could unlock massive demand for Zepbound by filling employer coverage gaps. Meanwhile, orforglipron shows superior results over Rybelsus in key trials.
5 min read
Mounjaro Shortage Harms Patients Amid Diet Craze: Supply Crisis
A surge in dieting demand has triggered shortages of Mounjaro's 5mg starting dose, making it hard for metabolic disease patients to access treatment. Clinics in Seoul report instability until late March, as non-reimbursed status leaves supply unmanaged. Patients like Mr. A face halted therapy despite proven benefits for diabetes control and weight loss.
6 min read
Fat Cells Burn Energy for Heat: Next Weight Loss Frontier
Fat tissue isn't just storage—it's a dynamic organ that can burn energy as heat, opening new doors for weight loss beyond appetite-suppressing drugs like Ozempic and Wegovy. Researchers are targeting brown and beige fat to boost calorie burn without triggering hunger. This could be the next era in metabolic therapies.
4 min read
Novo, Hims End GLP-1 Feud, Partner Again on Wegovy
The months-long GLP-1 feud between Novo Nordisk and Hims & Hers Health is over, with a new partnership to sell Wegovy via Hims' telehealth platform expected Monday. Following a recent lawsuit over copycat drugs, shares surged: Hims nearly 40%, Novo 2% after-hours. Analysts call it a surprise positive for expanded market reach.
5 min read
20% of Eligible Youth Prescribed GLP-1 RAs, Study Finds
Just 20% of youth eligible for GLP-1 receptor agonists due to obesity are actually prescribed these medications, according to a recent Pediatrics study. Prescribing favors older adolescents with higher BMI and specific racial groups, but interruptions due to cost affect nearly two-thirds. This highlights gaps in access to promising obesity treatments for teens.
5 min read
Zydus' ZYOG1: Oral GLP-1 Ahead of Ozempic by 15 Years
Fifteen years before Ozempic sparked the GLP-1 revolution, Zydus Lifesciences in India developed ZYOG1, a promising oral GLP-1 agonist. Showing preclinical benefits for glucose control, weight loss, and a clean safety profile, it earned phase I trial approval in 2010—but was shelved amid high costs. This untold story highlights India's early edge in peptide therapy.
5 min read
SNAC in Ozempic and Wegovy Tablets Raises Gut Health Questions, Study Finds
New research uncovers potential effects of SNAC—the hidden ingredient enabling Ozempic and Wegovy tablets—on gut health. In a 21-day animal study, repeated exposure led to shifts in harmful gut bacteria, elevated inflammation, and depleted cognitive proteins. While not proving harm in humans, findings urge caution as oral semaglutide use surges.
6 min read
73M Overweight Urban Indians, GLP-1 Awareness <5%: Kantar Report
Urban India faces a metabolic crisis with 73 million overweight adults, yet GLP-1 therapy awareness hovers below 5%, per Kantar's latest report. Despite high weight loss intent, a stark knowledge gap limits adoption of these diabetes and obesity treatments. Explore the data, demographics, and paths forward for better metabolic health.
5 min read
New Diet Lowers Methionine & Cysteine to Trigger Fat Burning Without Exercise
Lab mice shed pounds when key amino acids—methionine and cysteine—were cut from their diet, igniting fat burning without exercise. A University of Southern Denmark study shows this diet-induced thermogenesis boosted calorie burn by 20%, nearly matching constant cold exposure. This could redefine obesity treatments beyond GLP-1 drugs.
6 min read
Novo Nordisk Stock Erases Wegovy Gains After CagriSema Miss
Novo Nordisk's stock has erased the last of its Wegovy-driven gains in a brutal week, down 21% after next-gen obesity drug CagriSema underperformed rivals. Despite 20.2% weight loss in trials, analysts downgrade amid patent cliffs and competition from Eli Lilly's tirzepatide. The company's pivot to oral Wegovy offers hope, but diversification pressures mount.
5 min read
$3,000 Minipigs Powering Europe's Drug Pipeline
In eastern Denmark, Ellegaard Gottingen Minipigs A/S breeds specialized $3,000 minipigs vital to Europe's drug pipeline, including Novo Nordisk's Ozempic and Wegovy. These biosecure facilities address supply chain vulnerabilities exposed by the pandemic's monkey shortages. As the EU pushes for biotech independence, these smaller, human-like pigs offer a strategic alternative.
6 min read
Tirzepatide Activates Brown Fat to Burn Calories, Mouse Study Shows
Tirzepatide doesn't just curb hunger—it may directly rev up fat-burning brown adipose tissue, according to a groundbreaking mouse study. Researchers separated its metabolic effects from simple calorie restriction, uncovering benefits for energy expenditure and blood glucose control. This could pave the way for more effective obesity therapies.
6 min read
Viking Therapeutics Shares Surge 12% as Novo's CagriSema Stumbles
Shares of Viking Therapeutics surged approximately 12% on Monday following a clinical setback for Novo Nordisk's next-generation obesity drug CagriSema, which underperformed Eli Lilly's Tirzepatide in a pivotal Phase 3 trial. This shift highlights intensifying competition in the GLP-1 obesity market. Investors are eyeing Viking's VK2735 as a promising contender.
5 min read
Study Flags Gut Risks from SNAC in Oral Weight-Loss Pills
A groundbreaking study from Adelaide University is raising questions about SNAC, the ingredient making oral weight-loss drugs like semaglutide tablets viable. In a 21-day animal model, repeated SNAC exposure linked to lower beneficial gut bacteria, reduced protective compounds, and elevated inflammation markers. As tablet versions gain popularity, experts call for more research on this component's full impact.
6 min read
Obesity Rates Rising to 50% by 2030 Despite GLP-1s: What It Means
Despite the buzz around GLP-1 medications like Wegovy and Zepbound, obesity rates in the U.S. are projected to hit nearly 50% by 2030, per a New England Journal of Medicine study. Severe obesity (BMI 40+) continues to rise, highlighting disparities in food access and demographics. UVA expert Dr. Cate Varney breaks down what this means for public health and patients.
6 min read
Novo Nordisk to Meet US Wegovy Pill Demand First, CEO Doustdar Says
Novo Nordisk is prioritizing the US market for its popular Wegovy pill to prevent shortages like those seen with injectable semaglutide. CEO Mike Doustdar emphasized a country-by-country rollout strategy amid legal battles against compounders and competition from Eli Lilly. With 246,000 US users already on the oral obesity drug, supply stability is key.
5 min read
Lilly's $1.5B Orforglipron Inventory Grows Ahead of FDA Obesity Nod
Eli Lilly is stockpiling $1.5 billion worth of its oral obesity drug orforglipron to avoid the supply shortages that hampered early GLP-1 launches. With an expected FDA decision on April 10, the company aims for a swift global rollout against Novo Nordisk's Wegovy pill. This strategic move signals big changes in accessible weight loss therapy.
5 min read
Amazon Pharmacy Expands Same-Day Delivery to 4,500 US Cities
Amazon Pharmacy is set to revolutionize prescription access by expanding same-day delivery to about 4,500 US cities and towns by the end of 2024, reaching nearly 2,000 new communities. This includes states like Idaho and Massachusetts, building on partnerships for GLP-1 obesity treatments with WeightWatchers. Patients managing metabolic health conditions can expect quicker delivery of essential medications.
5 min read
China Biotech Targets 2028 Trials for Semaglutide Nasal Spray Like Wegovy
A Shanghai-based biotech is developing a nasal spray version of semaglutide, the key ingredient in Novo Nordisk's Wegovy, with global clinical trials targeted for completion by 2028. This experimental weight-management spray promises lower costs than tablets and better suitability for long-term use. As Novo's patent nears expiration in China, competition heats up in the booming GLP-1 market.
4 min read
Weight-Loss Price Wars Upend Big Pharma's Model
Two years ago, GLP-1 prescriptions cost over $1,000 monthly for uninsured patients. Now, Wegovy's pill starts at $149, flipping Big Pharma's playbook amid fierce price wars. As Novo Nordisk forecasts sales drops and Eli Lilly surges, discover how consumer demand is reshaping obesity treatments.
6 min read
Weight-Loss Drugs Compete in Super Bowl Ads: Wegovy Leads
Weight-loss drugs like Wegovy's new pill are making a splash with multimillion-dollar Super Bowl ads featuring Kenan Thompson, DJ Khaled, and Serena Williams. As Novo Nordisk and Eli Lilly battle for market share, affordable oral GLP-1 options starting at $49 signal a new era in obesity care. See how these celebrity spots aim to reach 130 million viewers.
5 min read
Hit Weight Loss Goal on GLP-1s Like Ozempic? What Next?
GLP-1 medications like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) have helped 1 in 8 U.S. adults lose 15-20% body weight. But after hitting your goal, what now? Dr. Amy J. Sheer shares proven steps for maintenance, plateaus, and long-term success.
8 min read
Wegovy Funding in NZ: Case for Teens with Severe Obesity
New Zealand's Pharmac advisory panel has recommended funding Wegovy for chronic weight management in those with high BMI and related conditions. Paediatric endocrinologist Professor Wayne Cutfield argues strongly for including obese teens to prevent lifelong health crises. This guide breaks down the science, evidence, and implications.
5 min read
Wegovy Pill: 18,410 Prescriptions in First Full Week
Novo Nordisk's Wegovy pill recorded 18,410 U.S. prescriptions in its first full week after launch, surpassing other GLP-1 starts. Investors eye its edge over Eli Lilly in the competitive obesity market. Oral treatments offer needle-free flexibility for patients.
1 min read
Seoul Hoards 66% of GLP-1 Supply as High-Risk Areas Lack
Two-thirds of South Korea's GLP-1 obesity drugs, including Wegovy and Mounjaro, flow to Greater Seoul despite higher obesity rates elsewhere. This supply imbalance raises alarms over access for high-risk patients. Data reveals stark regional disparities in distribution.
2 min read
AbbVie: Amylin Alternative to GLP-1 for Obesity Treatments
AbbVie is bolstering its obesity portfolio with GUBamy, an amylin-based drug from Gubra as a GLP-1 alternative. Unlike gut hormone-mimicking GLP-1s like Wegovy and Zepbound, amylin targets pancreatic hormones for improved tolerability and muscle retention. The company eyes long-term efficacy amid a $150B market boom.
1 min read
Weight Loss Drugs Cessation Linked to Regain and Cardiac Hazards
A comprehensive analysis published in The BMJ reveals that discontinuing weight loss drugs leads to an average monthly regain of 0.4 kg, with full weight and cardiometabolic risks returning within two years. This regain occurs nearly four times faster than after dietary and lifestyle interventions, raising questions about the drugs' long-term effectiveness. Experts emphasize combining medications with healthy habits for sustainable obesity control.
3 min read
Elderly Americans Abandon Weight-Loss Medications in Droves
Senior citizens in the U.S. often discontinue highly effective weight-loss medications such as GLP-1 drugs shortly after starting them, resulting in regained pounds and diminished health advantages. Side effects, high expenses, and inadequate insurance coverage frequently play key roles in this trend. Experts advocate for better coverage and ongoing research to address these challenges for older populations.
5 min read
Roche Allocates $100 Million in Structure Licensing Pact to Bolster GLP-1 Standpoint
Roche has invested $100 million in a licensing agreement with Structure Therapeutics to protect its GLP-1 portfolio from patent challenges. The deal covers CT-996, an oral GLP-1 medication acquired from Carmot, and includes royalties on future sales. Analysts highlight how this move reinforces Structure's strong intellectual property in GLP-1 agonists.
3 min read
From Shots to Subscriptions: The Rebranding of GLP-1 Drugs
Pharmaceutical giants like Novo Nordisk and Eli Lilly are transforming GLP-1 drugs into everyday consumer products, introducing oral versions and emphasizing cash-pay models. This shift, driven by telehealth and apps, aims to make weight loss as accessible as online shopping, while experts raise concerns about medical oversight.
5 min read
Wegovy Pill May Expand Access to Obesity Treatments
The United States Food and Drug Administration has greenlit the initial tablet form of a GLP-1 drug designed for shedding pounds, which might considerably broaden availability of obesity therapies. Produced by the Danish firm Novo Nordisk, this daily Wegovy pill is set to debut in early January, with clinical trial participants averaging a 16.6% drop in body weight.
1 min read
Let Them Eat Cake: A Solution for Obesity Exists, Yet Only the Affluent Can Access It
Scientific advancements in obesity treatment have revolutionized weight management, but financial barriers ensure these benefits primarily serve the rich. From costly medications to inaccessible surgeries, the struggle reveals deep societal inequalities. Addressing this requires structural changes to make health equitable for all.
5 min read
More UK Men Using Weight Loss Injections as 'Significant Shift' Emerges
Recent research highlights a growing trend of British men turning to weight loss injections. Data indicates a significant shift in usage, with men increasingly adopting these treatments.
3 min read
The Heated Race to Dominate the Booming GLP-1 Medication Arena
The GLP-1 drug market is experiencing rapid growth, driven by the increasing demand for treatments for type 2 diabetes and obesity. Three major pharmaceutical companies are vying for market dominance.
3 min read